Treatment with PROSTVAC, nilutamide, and combination therapy in non-metastatic androgen independent prostate cancer patients.

Trial Profile

Treatment with PROSTVAC, nilutamide, and combination therapy in non-metastatic androgen independent prostate cancer patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2010

At a glance

  • Drugs Rilimogene galvacirepvec (Primary) ; Rilimogene galvacirepvec-rilimogene glafolivec (Primary) ; Rilimogene glafolivec (Primary) ; Nilutamide
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Nov 2010 New trial record.
    • 21 May 2002 Interim results presented at the 38th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top